Health Care

Scientists expect cure for cancer in 1 year

Scientists expect cure for cancer in 1 year”

The drug called as "MuTaTo" (multi-target toxin) now in development by AEBi under the leadership of CEO Dr. Ilan is essentially "on the scale of a cancer antibiotic-a disruptive technology of the highest order", which shall be the potential game changer against the world's deadliest disease "Cancer". Once the treatment is over, the cells generate cancer again.

The treatment will not be affected by mutations by using at least three targeting peptides on the same structure with a strong toxin. The experiment showed inhibited human cancer cell growth and had no effect on healthy mice cells, according to the paper.

A team of Israeli scientists is claiming that it has developed a medication that has the power to cure all types of cancer.

"Our results are consistent and repeatable", Aridor said.

As news stories hailing the discovery spread online, other cancer experts urged the public to approach the report with caution.

The team of scientist have also claimed to make the first-ever cure for the deadly disease as a cheap, effective with no or minimal side-effects. We've heard of cure-alls for cancer in the past that unfortunately have not panned out. This oversimplifies the fact that cancer is more than 200 different diseases, which behave differently and pose different treatment challenges.

Another doctor, meanwhile, told the Daily Mail that it's not likely there will ever be a surefire cure for cancer.

The treatment, known as MuTaTo, is said to essentially be a "cancer antibiotic" that boasts "disruption technology of the highest order".

Professor Justin Stebbing, an expert in cancer medicine and oncology at Imperial College London, U.K., told Newsweek that research at the Weizmann "is some of the best in the world".

It hasn't been trialed on humans yet, but has seen incredible success on animals. So let's be cautiously optimistic, I just don't want to provide false hope for cancer patients.

Dr Vince Luca, assistant professor of Cancer Biology at Moffitt Cancer Centre, echoed the concerns, saying that "very few peptide-based drugs have received FDA approval for oncology indications".

A cancer cell (white) being attacked by two cytotoxic T cells (red). More than 99.9 percent of the molecular processes within them are the same as the normal cells they originate from. Mutations in the targets - or downstream in their physiological pathways - could make the targets not relevant to the cancer nature of the cell, and hence the drug attacking it is rendered ineffective...

A lot of cytotoxic anticancer treatments aim at fast-growing cells but cancer stem cells do not grow fast and are able to escape the treatments. "Painful lessons have been learned trying to exploit drugs that do not target founding mutations".

If MuTaTo is successful, it has the potential to revolutionize cancer treatment and give hope to the millions of people who are diagnosed each year.

Like this



31 January 2019
Chelsea hero Nevin: Hazard will be frustrated with Hudson-Odoi hype
Hazard has 10 goals and 10 assists in the league this season, often playing up front in a "false nine" role to lead the attack. GMT on January 31, but clubs in the Chinese Super League have until February 28 to sign players.

31 January 2019
Minister warns against Brexit compromises which dilute backstop
Meanwhile EU negotiator Sabine Weyand warned that the risk of a no-deal was now "very high". The International Trade Secretary Liam Fox urged Tory MPs to support May.

31 January 2019
Joshua renews interest in Fury clash
Joshua believes Wilder overlooked the abilities of Fury, who was coming back from a very long layoff. Joshua has a date booked at Wembley stadium for a big fight night on April 13.

31 January 2019
Australian Open Champ Naomi Osaka Becomes Asia's First No. 1 in Tennis
In New York Osaka was faced by the most incensed Serena Williams but amazingly kept her calm to win a first major title. Open final in September, she was the eighth different woman since the 2017 Australian Open to win a Grand Slam title .

30 January 2019
Wall Street starts the week sharply lower amid disappointing revenue figures
It was a rare warning from Apple Inc., and its stock fell 9 percent in a day, wiping out about $67 billion in market value. Chief Financial Officer Andrew Bonfield told Reuters that profits this year will be weighed down by a higher USA tax rate.

30 January 2019
Big 12 Challenge Roundup: Washington helps Kentucky top Kansas 71-63
No. 9 Kansas and No. 8 Kentucky traded punches during a gritty, slugfest in the SEC/Big 12 Challenge Saturday afternoon. Quinndary Weatherspoon scored 27 points as the Bulldogs held off the Tigers in an SEC game in Starkville, Miss.

30 January 2019
Anthony Davis will only re-sign with the Lakers
And they waited until after the season to make the move - as opposed to pulling the trigger on a trade at the February deadline. Davis can become an unrestricted free agent in 2020 if he doesn't sign an extension.

30 January 2019
Tyson Foods recalls chicken nuggets due to possibility of rubber inside
The views expressed therein are not necessarily those of, its sponsors or advertisers. Class III: This is a situation where the use of the product will not cause adverse health consequences.

30 January 2019
Rabbi Matondo: Schalke enquire about Manchester City's Wales winger
Matondo has attracted widespread interest, particularly in Germany, and AC Milan made a late play for the 18-year-old. And Matondo won't even be the first youngster to leave the club this month.

30 January 2019
Keith Thurman beats Josesito Lopez, despite a scare
He weathered a storm in the middle rounds, with Lopez unleashing a fierce barrage in the seventh that had the champion in trouble. But Lopez had him on the run in the 7th, connecting with a huge left hook to Thurman's jaw and backing up the champion.